Tenosynovial Giant Cell Tumor Treatment Landscape: A Dual-Modality Race Targeting CSF1R

Summary

• TGCT tumors are driven by a chromosomal translocation involving chromosomes 1 and 2, which results in overexpression of colony-stimulating factor-1 (CSF-1) and promotes tumor proliferation.
• Currently available systemic therapies, such as Daiichi Sankyo’s TURALIO and Ono Pharma’s ROMVIMZA, provide options for patients with symptomatic or advanced disease by targeting key disease pathways and enabling more comprehensive management.
• The TGCT treatment pipeline is robust, with several late- and mid-stage candidates demonstrating encouraging efficacy and safety profiles. Notable advanced therapies include Pimicotinib (Abbisko Therapeutics) and Emactuzumab (SynOx Therapeutics Limited). 
• In addition, emerging candidates like AMB 051 (AmMax Bio, Inc.) are under development and may reach the market during the forecast period.

TGCT is a rare, typically benign but locally aggressive tumor arising from the synovium, bursae, and tendon sheaths, and is clinically classified into localized and diffuse forms. A recurrent chromosomal translocation between chromosomes 1 and 2 drives overproduction of colony‑stimulating factor‑1 (CSF1), which in turn fuels macrophage‑rich tumor growth, positioning the CSF1/CSF1R signaling pathway at the heart of TGCT biology.

Across the seven major markets, TGCT already accounts for an estimated half‑million TGCT prevalent cases as of 2025, with the United States alone contributing nearly 250,000 TGCT prevalent cases and the EU4, plus the UK, adding about 240,000. Within this population, localized disease dominates, but diffuse TGCT, including pigmented villonodular synovitis, is more aggressive, more disabling, and more prone to recurrence after treatment.

For decades, surgery has been the cornerstone of TGCT management, with marginal excision as the mainstay for localized disease and more extensive synovectomy required for diffuse TGCT. While localized tumors can often be controlled with conservative surgery, diffuse disease frequently recurs, driving repeated procedures, cumulative joint damage, and persistent symptoms.

NSAIDs and other symptomatic measures offer only transient relief and do not alter the underlying disease process, leaving a significant gap for patients who are unresectable or at high surgical risk. In Europe, key opinion leaders still describe a landscape where resection and even radiotherapy are used despite recurrence rates of roughly 30% and long‑term concerns such as radiation‑induced malignancy for a tumor that is itself benign.

Why CSF1R became the prime target in the TGCT?

The genetic and cellular underpinnings of TGCT have made CSF1/CSF1R signaling an attractive, druggable node. Overexpression of CSF1 attracts and activates CSF1R‑positive macrophages that populate and sustain the tumor mass, creating a dependency on this ligand–receptor loop.

The first wave of systemic agents exploited this vulnerability: CSF1R‑targeting therapies and off‑label tyrosine kinase inhibitors were deployed in advanced or unresectable cases to shrink tumor volume and improve pain, stiffness, and function. More recently, dedicated CSF1R inhibitors, small molecules, and antibody‑based agents alike, have begun to redefine the standard of care for patients who are not candidates for curative surgery or for whom surgery would cause unacceptable morbidity.

Approved CSF1R‑targeted small molecules: TURALIO and ROMVIMZA

TURALIO (pexidartinib, Daiichi Sankyo) was the first systemic therapy specifically approved for TGCT, and it set the template for small‑molecule intervention in this disease. Pexidartinib is an oral small‑molecule inhibitor that targets CSF1R alongside other kinases, including FMS‑like tyrosine kinase 3 and KIT, directly disrupting macrophage‑driven tumor growth.

In the Phase III ENLIVEN trial, pexidartinib achieved an objective response rate of 39.3% versus 0% with placebo in 120 TGCT patients, alongside clear improvements in tumor volume, mobility, physical function, stiffness, and pain. These benefits were tempered by notable hepatic toxicity, elevations in AST, ALT, and bilirubin led to treatment discontinuations and prompted stringent risk‑management measures, but the drug established proof of concept that systemically blocking CSF1R can deliver meaningful and durable responses.

ROMVIMZA (vimseltinib, Ono Pharmaceutical) represents the next generation of oral CSF1R inhibition and underscores the market’s momentum toward finely tuned small molecules. Approved by the US FDA in February 2025 for adults with symptomatic TGCT in whom surgery would worsen functional limitation or cause severe morbidity, ROMVIMZA subsequently secured European Commission approval later that year for a similar patient population.

In contrast, Japan currently lacks approved drug therapies for TGCT, where treatment primarily relies on surgical procedures, along with radiation and systemic approaches to manage the disease. By 2025, TURALIO and ROMVIMZA stood as the only approved systemic TGCT therapies in the US, with ROMVIMZA also available in the EU, while Japan remained reliant on surgical and non‑approved systemic options. Collectively, these agents helped drive the total TGCT market in the 7MM to an estimated USD ~320 million in 2025, with the US accounting for nearly USD 240 million of that value.

The rise of monoclonal antibodies and next‑wave small molecules

The TGCT pipeline now clearly bifurcates into highly selective small‑molecule CSF1R inhibitors and antibody‑based CSF1R antagonists, each bringing distinct pharmacology, dosing formats, and potential positioning across the patient journey.

Abbisko Therapeutics’ Pimicotinib: Refining oral CSF1R blockade

Pimicotinib (ABSK021, Abbisko Therapeutics) is an orally available, highly selective small‑molecule inhibitor of CSF1R designed specifically for macrophage‑driven diseases, including TGCT. By inhibiting CSF1R signaling, pimicotinib aims to reduce macrophage‑mediated tumor proliferation and inflammation while potentially offering a more refined safety and tolerability profile than earlier multi‑target agents.

The program has advanced rapidly: Abbisko’s New Drug Application for pimicotinib in TGCT was formally accepted by the US FDA in January 2026, and the drug is one of the most advanced late‑stage candidates in the TGCT pipeline with expected US approval around 2027. 

According to Stuti Mahajan, consulting manager at DelveInsight, pimicotinib is projected to emerge as a key revenue contributor among emerging therapies, reflecting both its oral route and its fit for long‑term systemic disease control.

SynOx Therapeutics’ Emactuzumab: Antibody‑driven CSF1R inhibition

On the biologics front, emactuzumab (SynOx Therapeutics) exemplifies how monoclonal antibodies can be harnessed to modulate the same pathway from a different therapeutic angle. Emactuzumab is described as a potent and selective CSF1R inhibitor with platform potential across macrophage‑driven inflammatory, fibrotic, and neovascular conditions. Administered intravenously, it blocks CSF1R signaling mediated not only by CSF1 but also by IL‑34, offering a broader lever over macrophage activation and survival.

SynOx is evaluating emactuzumab in the Phase III TANGENT study for patients with unresectable localized or diffuse TGCT, directly addressing one of the most difficult‑to‑treat subsets. Patient enrollment for TANGENT was completed in August 2025, and top‑line results are anticipated in the first quarter of 2026, a milestone that could open an antibody‑based systemic option to complement or even compete with oral CSF1R inhibitors.

AmMax Bio’s AMB 051: Local CSF1R antagonism inside the joint

AMB 051 (AmMax Bio) highlights a third strategic avenue: local, intra‑articular CSF1R antagonism. Positioned as a macrophage CSF1R antagonist in Phase II development with intra‑articular administration, AMB 051 aims to concentrate its effect within the affected joint while potentially limiting systemic exposure.

If successful, Mahajan said, AMB 051 could carve out a niche between surgery and fully systemic therapy, particularly for patients with localized but recurrent disease where joint‑level control is paramount and repeated resections are undesirable.

What lies ahead in the TGCT treatment space?

The future of TGCT treatment is rapidly evolving from a surgery-dominated paradigm to a more nuanced, biology-driven continuum of care, where systemic, local, and potentially combination therapies are integrated based on disease burden, location, and patient-specific functional goals.

One of the most defining shifts will be the expansion and stratification of CSF1R-targeted therapies. As next-generation agents such as pimicotinib and emactuzumab mature clinically, differentiation will likely hinge on selectivity, safety, durability of response, and convenience of administration. Oral small molecules may continue to dominate in chronic disease control, while monoclonal antibodies could find a role in patients requiring deeper or more sustained macrophage depletion, particularly in refractory or high-burden diffuse TGCT.

At the same time, the field is expected to move toward earlier use of systemic therapy, including neoadjuvant settings to shrink tumors before surgery, enabling less invasive procedures and better joint preservation. This approach could be particularly transformative in diffuse TGCT, where surgical morbidity remains high and recurrence common.

Another important frontier is localized, joint-directed therapy, as exemplified by intra-articular CSF1R antagonists like AMB 051. Such approaches may redefine treatment for patients with recurrent yet anatomically confined disease, offering targeted control while minimizing systemic toxicity. If validated, this could create a middle ground between repeated surgery and lifelong systemic therapy.

The incorporation of biomarker-driven treatment selection is another anticipated evolution. As understanding deepens around CSF1 expression levels, macrophage density, and alternative signaling pathways such as IL-34, clinicians may be able to better predict which patients will respond to specific modalities, enabling a more personalized treatment algorithm.

Finally, long-term disease management will increasingly emphasize quality of life, functional preservation, and chronic disease control. With TGCT often affecting younger, active individuals, therapies that balance efficacy with tolerability, convenience, and joint preservation will define future standards of care.